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Introduction
Exercise capacity measured by means of 6-min walk distance and/or peak oxygen uptake (VO 2max ) during cycle ergometry is independent predictor of mortality in patients with chronic obstructive pulmonary disease (COPD). 1e3 Depending on disease severity, patients suffer from mild to severe airflow limitations induced by the decline in smoking related lung function. 4 The resulting decrease in functional exercise capacity manifests itself as breathlessness upon only mild exertion markedly limiting quality of life. 5e7 The prevalence and incidence of COPD are rapidly increasing and a systematic reduction in disease specific risk factors must be actively targeted, in particular tobacco use. In addition, more awareness about short-and longterm health benefits associated with physical activity must be raised in terms of attenuating disease progression. 8 Several systematic reviews of chronic disease management have shown that integrated care programs with an interdisciplinary approach and emphasis on selfmanagement maximize long-term patient outcome. 9e11 In this regard, regular physical activity plays an important role in chronic disease management and has been associated with a slower decline in smoking related lung function, a reduction in hospital admissions and overall improvement in survival rates among COPD patients. 1 Therefore, encouraging patients to become more physically active has become a major focus in modern COPD therapy. 12e14 The use of accelerometers to measure physical activity levels in free living conditions is rapidly increasing in literature and many studies have employed these devices to investigate possible relationships between physical activity levels and clinical outcome. 6,7,15e19 Likewise, previous investigators have demonstrated clinically useful associations between accelerometer derived activity data and functional status in patients with COPD. 4, 6, 7, 14 Nevertheless, detailed analyses of accelerometer derived activity data in terms of activity mode, duration, frequency and intensity and their dependent and independent relation to disease severity are scarce in patients with COPD.
The purpose of this study was therefore to evaluate different aspects of accelerometer derived activity data in a well-characterized cohort of COPD patients in order to extrapolate reliable identifiers of disease severity. We suspect that not only the total activity volume is crucial in terms of disease severity, but also the intensity with which the activity is performed is a key outcome parameter.
Methods

Setting and study population
This prospective cohort study assessed daily physical activity in COPD patients recruited in the "Predicting Effects and Risk Factors in Exacerbations of Chronic obstructive pulmonary disease" (PROMISE) study. 20 Data from 107 patients included in the stable state at the Clinic of Pulmonary Medicine of the University Hospital Basel, Switzerland, between November 2008 and March 2010 were analyzed. In brief, one of the primary end-points of the study was to explore predictors that might identify recurrence and poor outcome during and outside exacerbations.
To be eligible for the study, patients had to be diagnosed with COPD on the basis of clinical history, physical examination, and to meet post-bronchodilator spirometric criteria for COPD Stage IIeIV according to the GOLD guidelines at inclusion. Spirometry was performed by trained lung function technicians according to American Thoracic Guidelines at inclusion. 12 Immunocompromised patients, patients with cystic fibrosis, active pulmonary tuberculosis or infiltrates on chest radiographs upon presentation were excluded from the evaluation.
Regular follow-up visits were scheduled every 6 months and unscheduled visits at exacerbation and at recovery from exacerbation (after 4 weeks) were provided after inclusion. Both the baseline visit and follow-up assessments included detailed medical history, such as smoking status, current medication, duration of disease, co-morbidities, physical examination, quality of life questionnaires (SF-36), 21 Saint Georges Respiratory Questionnaire (SGRQ), 22 Modified Medical Research Council Dyspnea Scale (MMRC), spirometry, chest X-ray, 6-min walking test and accelerometry.
The 6-min walking test was conducted in an enclosed corridor on a measured course that was 40 m in length according to the ATS guidelines. The course was marked every 5 m, and subjects were instructed to walk from one end to the other end, covering as much distance as possible during the 6 min. Patients were verbally encouraged and remaining time was called out after every elapsed minute. Subjects were allowed to rest if needed. The BODE index was computed based on a point value system including the following variables: FEV 1 % of predicted, distance walked in the 6 min walk test in meters, MMRC dyspnea scale (IeIV) and body mass index (h 2 /w), as previously described. 23 Spontaneously expectorated sputum samples were obtained and examined using standard techniques. 24 Daily activity monitoring by means of accelerometry was monitored over eight days at the stable state of the disease starting at scheduled visits. The study was carried out according to the principles of the Declaration of Helsinki and approved by our local ethics committee (Ethic Commission Beider Basel EKBB 295/07). Written informed consent was obtained from all participating patients.
Sample size calculation
This PROMISE study defines rather several scientific goals instead of a single primary end-point. 20 This approach is believed to optimize information extraction, thereby unrestricting data analysis in the context of a noninterventional, longitudinal study. Power calculation was based on the conservative assumption of a 20% recurrence rate of acute exacerbation requiring hospitalization and/or death within two-year follow-up. Thus, the inclusion of 600 patients is expected to result in 120 patients developing a major clinical end-point during the study period. The sample size is expected to allow subgroup comparisons and analysis for clinically significant clinical outcomes. The analysis of physical activity in a subgroup of the study population was a pre-defined secondary end-point of the protocol. Subgroup analysis, however, was not based on a power calculation.
Accelerometer activity monitoring
Patients were handed the accelerometer (Aipermon Ò GmbH, Germany) during a schedule visit and instructed to wear it whilst going about their daily business. The device was attached to the patient's belt and positioned above the left hip. Patients were encouraged to wear the device continuously during normal waking hours for eight consecutive days. The accelerometer was to be attached upon rising in the morning and only to be taken off for showering, bathing and sleeping. The first and last day were excluded from the analysis. Therefore only six consecutive days were included in the statistical analysis (a day started at 24.00 o'clock and ended at 24.00 o'clock the same day). All device settings were pre-programmed for each patient upon receiving it and the device was switched on throughout the entire measurement period to keep patient handling of the accelerometer to a minimum. Upon return, the data were copied onto a PC, and its contents were viewed via ActiCoach MPAT2Viewer, Aipermon Ò . Wearing time included min/day spent passively (PAS: sitting), actively (ACT: movement, but not walking), walking (WLK: 0e5 km/h) and fast walking (FWLK: >5 km/h). These were computed and analyzed. Walking speeds from 0 to 80 m/ min were detected as Walking and walking speeds from 83 to 115 m/min were detected as Fast Walking. Speeds above 115 m/min were considered Sportive at which point walking would turn into jogging in most individuals. The thresholds used to classify walking speeds are set forth by the manufacturer based on walking behavior in healthy individuals. Non-wearing time was indicated by the device as "resting mode". Walking and fast walking times were added to a total walking time (TWT). Activity modes and accelerometer detection accuracy were extensively validated and detailed results are reported elsewhere. 25 In summary, the device was able to accurately detect steps to 99% at walking speeds ranging as low as 20 m/min onwards.
Data analysis
Statistical analysis was done using SPSS software (version 17.0, SPSS Inc.). Data were descriptively analyzed reporting mean AE standard deviation (SD) for quantitative measurements and percentages for frequencies. Bivariate correlations of non-parametric variables were investigated using SpearmaneRho correlation coefficient (R). Statistical comparisons between two unrelated measurements were assessed by one-way ANOVA for comparison across GOLD stages. In all data analyses, P-values less than 0.05 were considered as statistically significant. A multivariable logistic regression model was applied with BODE index !6 as the dependent variable. Statistically significant independent predictors of this model were evaluated. Receiver operating characteristic (ROC) analyses were performed to determine the most reliable cut-off value in terms of correct classification of patients with advanced stages of COPD (BODE index !6) based on the parameter TWT and FWLK (maximizing sum of sensitivity and specificity). The area under the ROC-curve (AUC) was reported to assess overall diagnostic performance of potential explanatory variables (TWT and FWLK). Ninety-five percent confidence intervals were reported for AUCs indicating statistically significant diagnostic capability if the critical value of 0.5 is not included. Statistically significant independent predictors of this model were evaluated.
Results
Patient characteristics
A total of 107 patients were included in the study. Demographics of the study population are depicted in Table 1 (co-morbidities and medication use is depicted in Table 1 continued which is presented in the Online Supplement only). Mean age of patient population was 65.3 AE 10.8 years and 70% were men. Most patients were taking a long acting anticholinergic agent (79%) and a combination of LABA/ICS 82 (77%).
Activity data
The overall mean wearing time of the accelerometer was 10.9 AE 2.8 h/day ( Table 2 ). The overall mean non-wearing time of the accelerometer was 13.1 AE 2.8 h/day. There was no statistical difference in min/day spent PAS or ACT, however, there was a statistically significant difference (P < 0.01) in WLK, FWLK, TWT, distance, steps per day and kcal between GOLD II, III and IV. All significant correlations between activity measures and clinical parameters are listed in Table 3 .
To analyse the prognostic ability of accelerometer derived activity parameters in terms of probability of poor prognosis, a multivariable logistic regression analysis was performed with BODE index !6 as the dependent variable, age (years), PAS, ACT, FWLK, and TWT as covariates. Based on this model, TWT (min/day) and FWLK (min/day) were the only significant predictors of BODE index !6 (TWT: P Z 0.029 and FLWK: P Z 0.040, respectively) Table 4 (Online Supplement only). ROC analysis was performed to determine the best cut-off values for discriminating patients into BODE index !6 based on these parameters. The corresponding AUC-value with 95% CI for the parameter TWT was 0.80 (95% CI: 0.70e0.90) and the AUC-value with 95% CI for the parameter FWLK was 0.87 (95% CI: 0.81e0.94). ROC analyses showed the optimal cut-off value for TWT determined by Youden's index being 33.3 min/day with sensitivity of 86% and specificity of 70% and the optimal cut-off value for FWLK being 0.10 min/day (6 s) with sensitivity of 93% and specificity of 76% (Fig. 1) . Fig. 2 depicts the probability of patients with BODE index !6 based on walking intensity and in relation to age categorized by median age, i.e. N Z 50%, patients ! 70 and patients < 70.
Discussion
The main finding of this study is that accelerometer derived walking time in terms of volume (min/day) and intensity is significant and independent predictor of disease severity in patients with COPD. Daily walking time and intensity can be used to predict the probability of poor prognosis in patients with COPD, i.e. BODE index !6 with corresponding optimal cut-off values of 33 min/day for total walking time and 0.1 min/day for fast walking time. This information has potential clinical perspective in terms of long-term patient monitoring and screening due to its simplicity and applicability to patients' daily practical routine and coping abilities.
Although total steps per day were also indicative of functional exercise capacity and COPD severity, walking time and intensity showed the strongest association with both parameters. Activity data demonstrated that daily walking activity, in particular walking intensity, is severely impeded in patients with severe COPD and/or likelihood of poor prognosis. This is most likely due to severe breathlessness patients experience in daily life even during simple habitual activities such as walking around the house and/or at the supermarket. In patients with poor prognosis (BODE index !6), total daily walking times were accumulated throughout the day by short intermittent walking spurts (ca. 5 min) as opposed to single continuous segments (!30 min). This suggests a marked impairment in functional In this study, a marked decrease in walking times and intensity can already be seen in the early stages COPD such as GOLD stage II patients. This is in accordance with findings presented by Troosters et al. 6 In fact, when comparing GOLD stage II patients in our present study with previous data we obtained in patients with moderate to severe heart failure (NYHA III), 27 27 A moderate interaction between age, total walking time and intensity could be observed in our study population, albeit not significant. This might be due to the demographics of our study cohort and the fact that physical activity generally decreases with increasing age in most individuals independent of chronic diseases development.
In addition, disease severity in COPD typically manifests itself with increasing age. 26 The association between physical activity and disease severity has been illustrated by previous investigators, 7, 14, 28, 29 although our study is more detailed in its analysis. Moy et al. were able to demonstrate that higher amounts of daily physical activities in a small cohort of individuals with COPD were associated with higher FEV 1 % predicted and lower BODE index. 14 Controversially, other investigators have shown only weak correlations with lung parameters, particularly the degree of airway obstruction, and physical inactivity. 7, 19 Seemingly, Watz and colleagues 29 were able to link physical inactivity to higher values of systemic inflammation markers and concomitant co-morbidities such as left ventricular dysfunction. 29 We also found that the amount of physical inactivity (passive time) increased with disease severity, however, could not find any statistically significant predictive strength in terms of probability of poor prognosis for this parameter. Here too, an interaction with age could be extrapolated for this observation as both physical inactivity and disease severity increase with age.
Strengths and weaknesses of the study
The strengths of this paper include the detailed analysis of daily physical activity in a well-characterized cohort of COPD patients. Our findings could demonstrate that not only the amount of daily physical activity per se, but the intensity with which this habitual activity is performed 1 Roc-curve with corresponding AUC-value with 95% CI for TWT was 0.80 (95% CI: 0.70e0.90) and 0.87 (95% CI: 0.81e0.94) for FWLK. The corresponding optimal cut-off value for TWT was 33.3 min/day (sensitivity: 86%; specificity 70%) and FWLK was 0.10 min/day (sensitivity: 93%; specificity 76%).
Figure 2
Scatter plot illustrating the probability of patients with BODE index !6 based on walking intensity (min/day FWLK) and in relation to median age, i.e. N Z 50% of study population (age ! 70 or age < 70 years).
seems important in determining functional capacity and disease severity. This is an interesting new aspect, albeit has to be prospectively evaluated and its clinical relevance needs to be studied. Nevertheless, this new parameter opens interesting new research avenues regarding the use of accelerometer monitoring in COPD patients in order to explore possible advantages to currently used parameters such as 6-min walk test and VO 2 peak in reflecting clinical prognosis. Such advantages could include continuous patient monitoring in a real life setting, lower hospital based resource requirements such as space and time limitations and need for medically trained personal. There are several limitations to this study. As mentioned above, these findings must be confirmed in a prospective study design to demonstrate a clear connection with clinical prognosis. Moreover, the practicability of using activity monitoring needs to be assessed in a clinical service oriented setting as opposed to a research setting. Our study population is limited in size and did not include any patients at early stage of COPD (GOLD I) and/or control subjects. In addition, there was no separate power calculation performed for this subgroup analysis. Lack of power could therefore explain some non-significant relationships presented in our study results. Nevertheless, statistical power is provided in the confidence intervals of the ROC analysis presented in our data analysis underlining the validity of the findings presented in this study.
In conclusion, we could show that daily walking time and intensity are closely linked to functional capacity and disease severity in patients with COPD and can be used to predict the probability of poor prognosis (BODE index !6). This information might facilitate long-term patient screening and continuous monitoring, thereby optimizing long-term chronic disease management.
